JNJ-40255293 is an adenosine A2A/A1 antagonist with efficacy in preclinical models of parkinson's disease.
Uses
JNJ-40255293 is a high-affinity human A 2A receptor antagonist with a KiKi of 7.5 nM. JNJ-40255293 can be used in the research of neurodegenerative diseases such as Parkinson's disease[1].
in vivo
JNJ-40255293 (0.1-10 mg/kg, p.o.) can reverse haloperidol (HY-14538)-induced catalepsy in male Balb/c mice. In male Wistar rats, JNJ-40255293 also dose-dependently reversed haloperidol (0.63 mg/kg, subcutaneous injection)-induced catalepsy, enhanced active arousal, and significantly reversed reserpine (HY-N0480 ) caused deficits in motor activity[1].
References
[1] John R Atack, et al. JNJ-40255293, a novel adenosine A2A/A1 antagonist with efficacy in preclinical models of Parkinson's disease. ACS Chem Neurosci. 2014 Oct 15;5(10):1005-19. DOI:10.1021/cn5001606
![2-amino-8-(2-morpholinoethoxy)-4-phenyl-5H-indeno[1,2-d]pyrimidin-5-one Structure](/CAS/GIF/1147271-25-7.gif)
